HomeTOP STORIESSkye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with... Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy By rogerjudd March 11, 2026 FacebookTwitterPinterestWhatsApp Post Content Previous articleAlberto Carvalho, Suspended LAUSD Chief, Denies WrongdoingNext articleBlend Labs signals $28.5M–$30M Q1 2026 revenue target as pipeline shifts to bundled deals and AI adoption accelerates latest articles Eastman Kodak shares jump on strong Q4 revenue and profit gains Metasphere Labs targets up to $1M raise via life offering U.S. KC-135 Refueling Plane Crashes in Iraq, Military Says Rescue operations under way after US refuelling plane crashes in Iraq Mattr Non-GAAP EPS of C$0.04, revenue of C$312.5M; gives Q1 and FY26 outlook Pono Capital Four prices $120M IPO at $10 per unit explore more Eastman Kodak shares jump on strong Q4 revenue and profit gains Metasphere Labs targets up to $1M raise via life offering U.S. KC-135 Refueling Plane Crashes in Iraq, Military Says Rescue operations under way after US refuelling plane crashes in Iraq Mattr Non-GAAP EPS of C$0.04, revenue of C$312.5M; gives Q1 and FY26 outlook Pono Capital Four prices $120M IPO at $10 per unit
